CEVEC Pharmaceuticals develops therapeutic proteins and monoclonal antibodies with human glycosylation patterns.
CEVEC is a center of expertise for the production of biopharmaceuticals using a unique human cell-based expression system.CAP-Go enables the production of proteins “beyond antibodies”. Complex, glycosylated proteins represent a significant portion of the human proteome and are notoriously difficult to express in conventional cell lines such as CHO. The CAP-Go expression platform comprises a portfolio of glyco-optimized human suspension cell lines for the highly efficient production of a broad range of difficult to express recombinant proteins with authentic human post-translational modifications or on demand tailor-made glycosylation patterns.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jul 25, 2011 | Series Unknown | €6M | 1 | — | — | Detail |
Feb 2, 2010 | Series B | $5.40M | 1 | — | — | Detail |
Nov 19, 2009 | Series A | €4M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
ERP Startfonds | — | Series Unknown |